Galectin‐1 and galectin‐3 expression in human bladder transitional‐cell carcinomas
Luca Cindolo, Lorenzo Chiariotti(San Salvatore Hospital), Paola Salvatore(San Salvatore Hospital), Vincenzo Mirone(University of Naples Federico II), Domenico Prezioso(Federico II University Hospital), Raffaela Pero(Institute for Experimental Endocrinology and Oncology), Gaetano Salvatore(University of Naples Federico II), Vincenzo Altieri(University of Naples Federico II), Carmelo B. Bruni(Institute for Experimental Endocrinology and Oncology), Giovanna Benvenuto(Institute for Experimental Endocrinology and Oncology)
International Journal of Cancer
February 19, 1999
Cited by 6
Related Papers
Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group
|Archivio Italiano di Urologia e Andrologia|2015|202
Prevalence, Incidence Estimation, Risk Factors and Characterization of Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Urological Hospital Outpatients in Italy: Results of a Multicenter Case-Control Observational Study
|The Journal of Urology|2007|181
Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
|European Urology|2008|128
Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas
|International Journal of Cancer|1999|97
Italian validation of the International Consultation on Incontinence Questionnaires
|British Journal of Urology|2005|84